“Blood glucose related adverse drug reaction of antitumor monoclonal antibodies: a retrospective analysis using Vigibase” (2023) Brazilian Journal of Pharmaceutical Sciences, 59, p. e18893. doi:10.1590/s2175-97902020000118893.